…
Deltagen Inc. provides drug discovery tools and services to the biopharmaceutical industry. The company offers a suite of programs designed to enhance the efficiency of drug discovery, including access to biological models, as well as small-molecule and secreted protein drug targets. It also provides target validation data in the areas of immunology and metabolic diseases. The company was incorporated in 1999 and is headquartered in San Mateo, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Deltagen Inc (DGEN.US) is quoted on the OTC Pink market but public disclosures and current filings do not clearly describe the company's core business or operations. Because verifiable operating details are scarce, long-term growth drivers cannot be confirmed; any potential upside depends on future disclosure, proven revenue generation and audited financial reporting, which may benefit investors if delivered.
Material risks include limited disclosure and absence of audited financials, low trading liquidity and high share-price volatility, regulatory or delisting risk and difficulty assessing management and financial condition.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2010-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2010-12-31 |
| Income before tax | -0.05M | 0.16M | -4.42M | -1.17M | -0.69M |
| Minority interest | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Net income | -0.05M | 0.16M | -4.42M | -1.17M | -0.69M |
| Selling general administrative | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Gross profit | 0.77M | 0.77M | 0.66M | 0.71M | - |
| Ebit | -0.05M | 0.16M | 0.11M | 0.00M | -0.69M |
| Ebitda | - | - | - | - | -0.67M |
| Depreciation and amortization | - | - | - | - | 0.01M |
| Operating income | -0.05M | 0.16M | 0.11M | 0.00M | -0.69M |
| Other operating expenses | 0.81M | 0.61M | 0.55M | 0.71M | 2.68M |
| Interest expense | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Extraordinary items | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Non recurring | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Other items | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Income tax expense | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Total revenue | 0.77M | 0.87M | 1.02M | 1.05M | 1.99M |
| Total operating expenses | 0.82M | 0.71M | 0.91M | 1.05M | 2.67M |
| Cost of revenue | 0.00M | 0.10M | 0.36M | 0.34M | - |
| Total other income expense net | 0.00M | 0.00M | -4.53M | -1.17M | 0.01M |
| Discontinued operations | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Net income from continuing ops | -0.05M | 0.16M | -4.42M | -1.17M | - |
| Net income applicable to common shares | -0.05M | 0.16M | -4.42M | -1.17M | - |
| Breakdown | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2010-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2010-12-31 |
| Total assets | 1.80M | 1.84M | 2.04M | 6.45M | 7.15M |
| Intangible assets | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Other current assets | 0.00M | 0.00M | -0.00M | 0.00M | 0.56M |
| Total liab | 0.13M | 0.12M | 0.44M | 0.40M | 0.32M |
| Total stockholder equity | 1.67M | 1.72M | 1.60M | 6.05M | 6.83M |
| Deferred long term liab | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Other current liab | 0.00M | 0.00M | 0.00M | 0.00M | 0.09M |
| Common stock | 0.04M | 0.04M | 0.04M | 0.04M | 0.04M |
| Retained earnings | -228.47M | -228.42M | -228.58M | -224.16M | -223.37M |
| Other liab | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Good will | 0.00M | 0.00M | 0.00M | 0.00M | 0.22M |
| Other assets | 1.59M | 1.59M | 1.59M | 1.59M | - |
| Cash | 0.05M | 0.02M | 0.09M | 0.10M | 3.53M |
| Total current liabilities | 0.13M | 0.10M | 0.44M | 0.30M | 0.32M |
| Net debt | - | - | - | - | -3.53M |
| Short term debt | 0.00M | 0.02M | 0.00M | 0.11M | - |
| Short long term debt | 0.00M | 0.02M | 0.00M | 0.11M | - |
| Other stockholder equity | 0.40M | 0.40M | 0.40M | 0.40M | 229.76M |
| Property plant equipment | 0.03M | 0.03M | 0.03M | 0.03M | - |
| Total current assets | 0.19M | 0.23M | 0.43M | 0.31M | 4.37M |
| Long term investments | 0.00M | 0.00M | 0.00M | 4.53M | - |
| Net tangible assets | 1.67M | 1.72M | 1.60M | 6.05M | - |
| Short term investments | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Net receivables | 0.12M | 0.19M | 0.33M | 0.16M | 0.29M |
| Long term debt | 0.00M | 0.03M | 0.00M | 0.10M | - |
| Inventory | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Accounts payable | 0.12M | 0.09M | 0.28M | 0.28M | 0.23M |
| Total permanent equity | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Noncontrolling interest in consolidated entity | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Temporary equity redeemable noncontrolling interests | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Accumulated other comprehensive income | 0.00M | 0.00M | 0.00M | 0.00M | 0.40M |
| Additional paid in capital | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Common stock total equity | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Preferred stock total equity | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Retained earnings total equity | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Treasury stock | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Non current assets total | - | - | - | - | 2.78M |
| Breakdown | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2010-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2010-12-31 |
| Investments | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Change to liabilities | 0.04M | -0.20M | 0.01M | -0.23M | - |
| Total cashflows from investing activities | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Net borrowings | 0.00M | 0.00M | 0.00M | -1.27M | - |
| Total cash from financing activities | 0.00M | -0.04M | -0.04M | -0.65M | - |
| Change to operating activities | -0.03M | -0.12M | 0.03M | 0.64M | - |
| Net income | -0.05M | 0.16M | -4.42M | -1.17M | -0.69M |
| Change in cash | 0.03M | -0.06M | -0.01M | -1.31M | - |
| Begin period cash flow | - | - | - | - | 5.70M |
| End period cash flow | - | - | - | - | 3.53M |
| Total cash from operating activities | 0.02M | -0.02M | -0.01M | -0.67M | -2.17M |
| Depreciation | 0.00M | 0.00M | 0.00M | 0.17M | 0.01M |
| Other cashflows from investing activities | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Dividends paid | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Change to inventory | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Change to account receivables | 0.06M | 0.14M | -0.16M | -0.09M | -0.16M |
| Sale purchase of stock | 0.00M | 0.00M | 0.00M | 2.05M | - |
| Other cashflows from financing activities | 0.00M | 0.00M | 0.00M | -1.27M | -1.50M |
| Change to netincome | 0.00M | 0.00M | 4.53M | -0.00M | - |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | - | - | - | - | -1.51M |
| Other non cash items | - | - | - | - | 0.01M |
| Free cash flow | - | - | - | - | -2.17M |
Sector: Healthcare Industry: Medical Instruments & Supplies
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| DGEN Deltagen Inc |
- -% |
0.00 | - | 21.93 | 3.57 | - | 0.01 | 0.12 |
| ISRG Intuitive Surgical Inc |
-5.75 1.27% |
445.88 | 43.30 | 31.35 | 12.25 | 7.35 | 11.63 | 30.22 |
| ESLOF EssilorLuxottica Société anonyme |
1.24 0.61% |
204.00 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 | 16.04 |
| ESLOY Essilor International SA |
3.80 3.90% |
101.21 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 | 16.04 |
| BDX Becton Dickinson and Company |
-1.36 0.69% |
195.03 | 31.62 | 13.76 | 2.25 | 2.04 | 2.93 | 13.40 |
Deltagen Inc. provides drug discovery tools and services to the biopharmaceutical industry. The company offers a suite of programs designed to enhance the efficiency of drug discovery, including access to biological models, as well as small-molecule and secreted protein drug targets. It also provides target validation data in the areas of immunology and metabolic diseases. The company was incorporated in 1999 and is headquartered in San Mateo, California.
1900 South Norfolk Street, San Mateo, CA, United States, 94403
650-345-7601
| Name | Title | Year Born |
|---|---|---|
| Dr. Robert J. Driscoll | CEO, Pres, Sec. & Director | 1966 |
| Mr. Daniel Ratto | Chief Financial Officer | 1958 |
| Dr. Robert J. Driscoll J.D., Ph.D. | CEO, President, Secretary & Director | 1966 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.